Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is listed today as Mirum Pharmaceuticals, Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jan 2026 | $68 M | Private placement after listing | $50 to $250 million | equity | SEC | |
| Dec 2020 | $10 M | Private placement after listing | $10 to $50 million | equity | SEC | |
| Nov 2018 | $60 M | No. 1 | $50 to $250 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Mirum Pharmaceuticals, Inc., its revenue in fiscal 2025 came from these product and service lines: Livmarli $360.01 million (69%), Bile Acid Medicines $161.31 million (31%).
Annual report (SEC XBRL) · Dec 2025
Mirum Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2026).
SEC Form D · Jan 2026
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Jan 2026
Products and services#
No products or services of Mirum Pharmaceuticals, Inc. are on record.
Investors#
12 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Deerfield Healthcare Innovations Fund, L.P. | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Deerfield Management Company, L.P. | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Deerfield Mgmt HIF, L.P | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Deerfield Mgmt IV, L.P. | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Deerfield Private Design Fund IV, L.P. | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Fhmls IX, L.L.C. | Other | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Fhmls IX, L.P. | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Frazier Life Sciences IX, L.P. | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Nea 16 GP, LLC | Other | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| NEA Partners 16, L.P. | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| New Enterprise Associates 16, L.P. | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Novo Holdings A/s | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 14 investors.
Largest shareholders today
Institutions holding Mirum Pharmaceuticals, Inc. shares, as of Sep 30, 2026.
- Frazier Life Sciences Management, L.P.$656 M11.76%
- Janus Henderson Group Ltd.$473 M8.48%
- BlackRock, Inc.$404 M7.24%
- FMR LLC$348 M6.24%
- Vanguard Portfolio Management LLC$225 M4.03%
- Price T Rowe Associates Inc /MD/$217 M3.90%
- Vanguard Capital Management LLC$214 M3.83%
- State Street Corp$204 M3.66%
- Wellington Management Group LLP$144 M2.59%
- Invesco Ltd.$131 M2.35%
- Geode Capital Management, LLC$124 M2.22%
- William Blair Investment Management, LLC$118 M2.12%
- Franklin Templeton Inc$107 M1.93%
- Eventide Asset Management, LLC$107 M1.91%
- Tang Capital Management LLC$106 M1.89%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Christopher Peetz | Executive officer | Jan 2026 |
| Eric Bjerkholt | Executive officer | Jan 2026 |
| Peter Radovich | Executive officer | Jan 2026 |
| Christopher J. Peetz | Executive officer | Dec 2020 |
| Edwin Jonathan Tucker | Executive officer | Dec 2020 |
| Ian J. Clements | Executive officer | Dec 2020 |
| Lara J. Longpre | Executive officer | Dec 2020 |
| Pamela Jonathan Vig | Executive officer | Dec 2020 |
| Peter J. Radovich | Executive officer | Dec 2020 |
| Michael Grey | Executive officer | Nov 2018 |
| Susan Dube | Executive officer | Nov 2018 |
| Christopher Peetz | Director | Jan 2026 |
| Laura Brege | Director | Jan 2026 |
| Laurent C. Fischer | Director | Jan 2026 |
| Lon C. Cardon | Director | Jan 2026 |
| Michael C. Grey | Director | Jan 2026 |
| Patrick C. Heron | Director | Jan 2026 |
| Saira C. Ramasastry | Director | Jan 2026 |
| Timothy Walbert | Director | Jan 2026 |
| William C. Fairey | Director | Jan 2026 |
| Christopher J. Peetz | Director | Dec 2020 |
| Edward T. Mathers | Director | Dec 2020 |
| Laura J. Brege | Director | Dec 2020 |
| Laurent J. Fischer | Director | Dec 2020 |
| Michael G. Grey | Director | Dec 2020 |
| Niall J. O'Donnell | Director | Dec 2020 |
| Patrick J. Heron | Director | Dec 2020 |
| Tiba J. Aynechi | Director | Dec 2020 |
| Chris Peetz | Director | Nov 2018 |
| Ed Mathers | Director | Nov 2018 |
| Jonathan Leff | Director | Nov 2018 |
| Michael Grey | Director | Nov 2018 |
| Patrick Heron | Director | Nov 2018 |
| Tiba Aynechi | Director | Nov 2018 |
About
Biopharmaceutical company.
Went public since 2019. Its SEC number is that of a company listed on a stock exchange.